UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TORULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of September 2018
Commission File Number: 001-38547
Autolus Therapeutics plc
(Translation of registrant’s name into English)
Forest House
58 Wood Lane
White City
London W12 7RZ
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover ofForm 20-F orForm 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted byRegulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ONFORM 6-K
Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, was incorporated in England and Wales on February 2, 2018.
In June 2018, the Company undertook a corporate reorganization pursuant to which (i) Autolus Therapeutics Limited became the direct holding company of Autolus Holdings (UK) Limited, a new holding company incorporated pursuant to the laws of England and Wales, (ii) Autolus Holdings (UK) Limited became the wholly owned subsidiary of Autolus Therapeutics Limited and the direct holding company of Autolus Limited, and (iii) Autolus Therapeutics Limitedre-registered as a public limited company and change its name to Autolus Therapeutics plc.
Autolus Therapeutics plc is submitting this Report onForm 6-K to furnish its (i) unaudited balance sheet as of March 31, 2018 for Autolus Therapeutics plc, (ii) unaudited condensed balance sheets as of March 31, 2018 and September 30, 2017 for Autolus Limited, Predecessor to Autolus Therapeutics plc, and (iii) unaudited condensed statements of operations and comprehensive loss for the six months ended March 31, 2018 and 2017 for Autolus Limited, Predecessor to Autolus Therapeutics plc, which are furnished herewith as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, to this Report onForm 6-K. The furnished balance sheets and statements of operations and comprehensive loss as of and for thesix-months ended March 31, 2018 do not reflect the corporate reorganization and initial public offering completed in June 2018.
EXHIBIT LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Autolus Therapeutics plc | ||||||
| Date: September 26, 2018 | By: | /s/ Andrew J. Oakley | ||||
| Name Andrew J. Oakley | ||||||
| Title: Senior Vice President, Chief Financial Officer | ||||||
